Evidence map›Paper›PMID 28301096›Full record

ArticleClinical pharmacology in drug development2017

Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.

Susanne Johansson, David P Rosenbaum, Marie Ahlqvist, Helen Rollison, Mikael Knutsson, Bergur Stefansson, Marie Elebring

Open access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology in drug development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. What's in the pipeline for lower functional gastrointestinal disorders in the next 5 years?American journal of physiology. Gastrointestinal and liver physiology · 2019
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Susanne JohanssonAstraZeneca Gothenburg, Mölndal, Sweden.
David P RosenbaumArdelyx Inc., Fremont, CA, USA.
Marie AhlqvistAstraZeneca Gothenburg, Mölndal, Sweden.
Helen RollisonAstraZeneca R&D, Cambridge, UK.
Mikael KnutssonAstraZeneca Gothenburg, Mölndal, Sweden.
Bergur StefanssonAstraZeneca Gothenburg, Mölndal, Sweden.
Marie ElebringAstraZeneca Gothenburg, Mölndal, Sweden.
AstraZeneca (Sweden) · SEArdelyx (United States) · USAstraZeneca (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tenapanor (RDX5791, AZD1722) is an inhibitor of sodium/hydrogen exchanger isoform 3 in development for the treatment of constipation-predominant irritable bowel syndrome and the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. We aimed to investigate whether tenapanor inhibits or induces cytochrome P450s (CYPs). In vitro experiments assessing the potential of tenapanor to affect various CYPs indicated that it could inhibit CYP3A4/5 (IC

Indexed as

AdultArea Under CurveCytochrome P-450 CYP3ADrug Administration ScheduleDrug InteractionsFemaleGene Expression RegulationHumansIsoquinolinesMaleMetabolic Clearance RateMidazolamMiddle AgedSulfonamidesYoung AdultCYP3A4 protein, humanCytochrome P-450 CYP3AIsoquinolinesMidazolamSulfonamidestenapanorcytochrome P-450 CYP3Acytochrome P-450 enzyme systemdrug interactionsmidazolamtenapanor

Identifiers

PMID28301096
PMCPMC5599994
OpenAlexW2595747660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.